Another ADC's with recent success in the treatment of other malignancies are brentuximab vedotin (BV) (an antibody–drug conjugate targeting CD30) and inotuzumab ozogamicin (a humanized CD22 monoclonal antibody linked to the cytotoxic agent calicheamicin) used in Hodgkin lymphoma [23] and the treatment of B cell malignancies [24], respectively. The gene discussed is CD22; the disease is Hodgkins lymphoma.